Agnes Choppin

Agnes Choppin serves as the Chief Scientific Officer at OTR3 since September 2021, and also works as an Independent Consultant in Preclinical Development for Biotech. Previously, Agnes held the role of Project Director R&D at Institut de Recherche Servier from September 2018 to December 2020, where responsibilities included project progression and scientific leadership. Additionally, Agnes has experience as Director of R&D, Search and Evaluation at the same institute, providing scientific insights on external licensing opportunities. Earlier roles include significant positions in preclinical development at companies like XOMA Royalty and Theron Pharmaceuticals, along with advisory roles in translational pharmacology at Bay Area companies. Agnes holds a PhD in Cardiovascular Pharmacology, a Master’s degree in Biology-Biochemistry, and a Bachelor’s degree in Biology from Pierre and Marie Curie University and Université Paris-Est Créteil.